Skip to main content
Warning Date
    2007-06-27

إدارة صحة كندا تحذر المستهلكين من استخدام أقراص إنكور للرجال وذلك لاحتمالية خطورتها على الصحة

2007-06-27

قامت صحة كندا بتحذير المستهلكين من استخدام أقراص إنكور للرجال Encore Tabs for Men وذلك بسبب احتوائها على كميات غير مصرح بها من مركبات صيدلانية مماثلة لما يتم استخدامه في الأدوية المصرح باستخدامها وهي مادة تادالافيل tadalafil حيث يستخدم هذا الدواء بوصفة طبية لعلاج أمراض العجز الجنسي لدى الرجال والذي يجب استخدمه تحت إشراف طبي.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2007-06-30

FDA SAFETY ALERT OF USING COLISTIMETHATE SOLUTION FOR INHALATION WITH NEBULIZER

2007-06-30

FDA notified healthcare professionals and cystic fibrosis patients in U.S that the Agency is investigating the possible connection between the use of a liquid solution of Colistimethate that was premixed for inhalation with a nebulizer and the death of a patient with cystic fibrosis (CF).

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2006-07-26

SSRIs and Treatment Challenges of Depression in Pregnancy

2006-07-26

FDA notified healthcare professionals and consumers of important information from two recent studies that should be considered when making treatment decisions in pregnant women who take antidepressants. The studies included pregnant women who were treated with selective serotonin reuptake inhibitors (SSRIs), or in a few cases, other antidepressant medications.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

FDA Warns Consumers About Dangerous Ingredients in "Dietary Supplements" Promoted for Sexual Enhancement

The U.S. Food and Drug Administration (FDA) is warning consumers not to purchase or consume Zimaxx, Libidus, Neophase, Nasutra, Vigor-25, Actra-Rx, or 4EVERON. These products are promoted and sold on web sites as "dietary supplements" for treating erectile dysfunction (ED) and enhancing sexual performance, but they are in fact illegal drugs that contain potentially harmful undeclared ingredients. These products have not been approved by FDA, and there is no guarantee of their safety and effectiveness, or of the purity of their ingredients.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

French health authorities ban cosmetics containing vitamin K1 (phytonadione)

The French Health Products Safety Agency (AFSSAPS) has announced a temporary ban on all cosmetic products containing vitamin K1 (INCI name: phytonadione; common name: phylloquinone; CAS: 84-80-0).

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2007-03-26

Heparin Sodium Injection 10,000 units/mL, and HEP-LOCK U/P 10 units/mL Medication Errors

2007-03-26

Audience: Pharmacists, neonatology/pediatric healthcare professionals

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2006-09-30

Highly Drug-resistant Tuberculosis, Worldwide Warning Given

2006-09-30

New forms of highly drug-resistant tuberculosis are emerging and action must be taken soon before they become widespread globally, says an editorial in this week's british medical journal. The authors say that urgent action is needed to implement effective tuberculosis control strategies, especially in countries where tuberculosis control practices have been inadequate.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2006-11-01

22 Hair Dye Chemicals Banned in Europe

2006-11-01

European regulators have banned 22 hair dye chemicals as part of a safety investigation prompted by a study linking dyes to bladder cancer.
But cosmetics industry officials tell WebMD consumers have little cause for concern, because the chemicals are virtually nonexistent in commercial hair products sold in Europe and the United States.
The ban, which takes effect Dec. 1, came as part of an overall safety review of hair dyes being conducted by the European Union's regulatory agency, the European Commission.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2006-11-22

Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia

2006-11-22

To evaluate risk of new-onset type 2 diabetes associated with use of selected antipsychotic agents, the authors conducted a new-user cohort study in a national sample of US Veterans Health Administration patients with schizophrenia (and no preexisting diabetes). The authors studied 15,767 patients who initiated use of olanzapine, risperidone, quetiapine, or haloperidol in 1999–2001 after at least 3 months with no antipsychotic prescriptions. Patients were followed for just over 1 year. New-onset diabetes was identified through diagnostic codes and prescriptions for diabetes medication.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2006-12-02

NSAIDs in First trimester Linked to Congenital Anomalies in Babies

2006-12-02

The findings of a new case controlled study has been published in the August issue of the journal Birth Defects Research Part B, which is published by John Wiley & Sons, states that congenital birth defects especially cardiac septal defects, could be associated with the use of NSAID by women in their first trimester.

Women who took first-trimester NSAIDs also had more than three times the risk of anomalies related to cardiac septal closure, mainly ventricular and atrial septal defects, the investigators found.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Subscribe to Drugs